Specifically, we evaluated the association between genetic variants and risk for adverse events, including NUDT15/TPMT and azathioprine (AZA)-induced myelosuppression, CYP2C19 and clopidogrel-related major adverse cardiovascular events (MACEs), ABCG2/CYP2C9/SLCO1B1 and statin-associated myopathy (SAMs), and CYP2C9 and non-steroidal anti-inflammatory drugs (NSAID)-linked gastrointestinal (GI) and renal toxicity. Here, CYP2C9 is linked to short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome.